Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Plain-language summary
This trial is testing chidamide (HDAC inhibitor) combined with azacitidine and other agents for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Chidamide (DRUG): chidamide 30mg biw, p.o, 21 days for a cycle. | Azacitidine (DRUG): 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle. | liposomal mitoxantrone (DRUG): 12mg/m2， d1,21 days for a cycle. | prednisone (DRUG): 60mg/m2，d1-5,21 days for a cycle.
Chidamide, Azacitidine, liposomal mitoxantrone, prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details